In the last 4 years, 6 phase 3 trials including a total of 27 023 patients with venous
thromboembolism (VTE) compared a direct oral anticoagulant (DOAC) with vitamin K …

Pulmonary embolism is a common and potentially fatal cardiovascular disorder that must be
promptly diagnosed and treated. The diagnosis, risk assessment, and management of …

Background—Dabigatran and warfarin have been compared for the treatment of acute
venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those …

Importance Thrombolytic therapy may be beneficial in the treatment of some patients with
pulmonary embolism. To date, no analysis has had adequate statistical power to determine …

Cancer‐associated thrombosis (CAT) is a major cause of morbidity and mortality in patients
with cancer. Over the past 2 decades, enormous advances have been made in the …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …

Despite the discovery and application of many parenteral (unfractionated and low-molecular-
weight heparins) and oral anticoagulant vitamin K antagonist (VKA) drugs, the prevention …

This guidance document focuses on the diagnosis and treatment of venous
thromboembolism (VTE). Efficient, cost effective diagnosis of VTE is facilitated by combining …

Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity
and mortality. VTE prevention and treatment are more complex in patients with cancer. The …

Importance Although retrievable inferior vena cava filters are frequently used in addition to
anticoagulation in patients with acute venous thromboembolism, their benefit-risk ratio is …